Patients with advanced solid tumors (e.g., gastric cancer, lung cancer)
Conditions
Interventions
Intervention Group:Multimodal Rehabilitation + Standard Antitumor Treatment Group
Control Group:Routine Antitumor Therapy + Basic Health Education
Sponsors
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 years or older; 2. Patients with histologically and/or cytologically confirmed diagnosis of advanced malignant tumors. 3. Currently undergoing antitumor therapy at the study site; 4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0–2 and/or Karnofsky Performance Status (KPS) score =60, indicating the ability to participate in light to moderate intensity physical activity. 5. Assessed by a specialist physician to be physically capable of safely engaging in the prescribed forms of exercise; for patients with comorbid chronic diseases (e.g., diabetes, hypertension), their conditions must be under basic control and not pose significant risks during exercise. 6. Willing to voluntarily participate in the study and able to provide written informed consent. If the subject lacks legal capacity to consent, the consent process must be conducted and signed by a legal guardian. If the subject is unable to read (e.g., illiterate participants), the consent process must be witnessed and signed by an impartial witness.
Exclusion criteria
Exclusion criteria: 1. Severe contraindications to exercise, including but not limited to serious cardiovascular, respiratory, neurological, or other medical conditions that may affect exercise safety (e.g., recent myocardial infarction, acute heart failure, severe osteoporosis with high fracture risk). 2. Patients with severe hepatic or renal insufficiency. 3. Patients with poorly controlled diabetes (fasting blood glucose >=13.3 mmol/L). 4. Uncontrolled pain (numeric rating scale >3); 5. Uncontrolled pleural or peritoneal effusion requiring repeated drainage; 6. Uncontrolled severe infections; 7. Uncontrolled deep vein thrombosis (DVT) of the lower limbs. 8. Patients at high risk of bleeding; 9. Vulnerable populations other than elderly or illiterate individuals, including those with psychiatric disorders, cognitive impairment, critically ill conditions, or pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of treatment-related adverse events (>= Grade 2, CTCAE); | — |
Secondary
| Measure | Time frame |
|---|---|
| Inflammatory Cytokines (IL-6?TNF-a);Fatigue Score;Hematological Parameters (Complete Blood Count, CBC);Plasma proteomics of inflammation, immunity, and metabolism-related proteins;Sleep quality score;Tumor Markers (e.g., CEA, CA19-9);Five Times Sit-to-Stand Test Time (5STS);Grip Strength;Physical Activity Level;Body Composition Score (BIA);Six-Minute Walk Test;Serum Nutritional Markers (e.g., Prealbumin, Albumin);Anxiety and Depression Score (HADS);Cognitive Function Score;Quality of life score (EORTC QLQ-C30);Immune Function Markers (Lymphocyte Subsets, Immunoglobulins);CT-based Body Composition Indicators (SMA, SMI, VFA);Composition of gut microbiota (e.g., species and abundance of bacteria); | — |
Countries
China
Contacts
Public ContactPan Qin
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Outcome results
None listed